Let’s Improve the Quality of Lives Together
At Processa, we develop drugs with a high potential return on investment and are designed to de-risk programs efficiently by targeted careful execution of clinical trials. We focus on drugs that have clinical evidence and treat conditions with a high unmet medical need.
We actively seek drug development opportunities that address unmet needs (preferably at a clinical stage of development) where we can apply our risk abated development strategy to provide design, development and execution of clinical study.
In-licensing
We have licensed in the following products:
Partnering
Consistent with the shift in priority, including the allocation of resources to our NGC drugs, Processa has begun and will continue to meet with potential licensing partners, as well as pursue other options to monetize PCS12852 and PCS499. If you are interested in speaking with us on these or other products, please contact us.
Ready to Partner Up?
Contact us with your questions about licensing, co-development, or other possibilities.